title: The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet.
abstract: The present review aims to assess the state-of-the-art regarding cost-effectiveness of therapy for secondary hyperparathyroidism in order to identify the best treatment and review methodological issues. PubMed and the Cochrane Library were searched to identify papers performing comparative analysis of costs and effects of treatment for secondary hyperparathyroidism in adult patients. Among the 66 papers identified, only 10 were included in the analysis. Treatment strategies evaluated in the selected papers were: cinacalcet in addition to vitamin D and phosphate binders versus vitamin D and phosphate binders only (seven papers), paricalcitol versus non-selective vitamin D (two papers), early and late introduction of cinacalcet in addition to vitamin D and phosphate binders (one paper) and paricalcitol versus cinacalcet (one paper). The high degree of heterogeneity among alternative treatments and methodological limits related to cost items considered, resource valuation methods and so on, make it unfeasible to reach a definite conclusion regarding cost-effectiveness but allow for future research opportunities.
authors.affiliation: Scuola Superiore Sant'Anna, Pisa, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Lorenzoni
authors.forename: Leopoldo
authors.initials: L
authors.lastname: Trieste
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Turchetti
mesh_terms: D000328:Adult; D002614:Chelating Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D000069449:Cinacalcet / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004872:Ergocalciferols / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications; D010710:Phosphates / Q000378:metabolism; D014807:Vitamin D / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use
chemical_list: D002614:Chelating Agents; D004872:Ergocalciferols; D010710:Phosphates; D014807:Vitamin D; C084656:paricalcitol; D000069449:Cinacalcet
keywords: calcimimetic; chronic kidney disease; cost-utility; cost–effectiveness; paricalcitol; phosphate binders; secondary hyperparathyroidism